Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1{gamma} autoantibodies
Conclusions
Anti-Sp4 autoantibodies appear to identify a subgroup of anti-TIF1-positive DM patients with lower cancer risk. (Source: Annals of the Rheumatic Diseases)
Source: Annals of the Rheumatic Diseases - January 23, 2023 Category: Rheumatology Authors: Hosono, Y., Sie, B., Pinal-Fernandez, I., Pak, K., Mecoli, C. A., Casal-Dominguez, M., Warner, B. M., Kaplan, M. J., Albayda, J., Danoff, S., Lloyd, T. E., Paik, J. J., Tiniakou, E., Aggarwal, R., Oddis, C. V., Moghadam-Kia, S., Carmona-Rivera, C., Milise Tags: ARD, Myositis Source Type: research
Genome ‐wide imputation identifies novel associations and localises signals in idiopathic inflammatory myopathies
ConclusionsWe report novel and strong associations in IIM and PM, and localise signals to single genes and immune cell types.This article is protected by copyright. All rights reserved. (Source: Arthritis and Rheumatology)
Source: Arthritis and Rheumatology - December 30, 2022 Category: Rheumatology Authors: Simon Rothwell,
Christopher I. Amos,
Frederick W. Miller,
Lisa G. Rider,
Ingrid E. Lundberg,
Peter K. Gregersen,
Jiri Vencovsky,
Neil McHugh,
Vidya Limaye,
Albert Selva ‐O'Callaghan,
Michael G. Hanna,
Pedro M. Machado,
Lauren M. Pachman,
An Tags: Brief Report Source Type: research
Efficacy and safety of rituximab treatment in patients with idiopathic inflammatory myopathies: A systematic review and meta-analysis
ConclusionRTX may be an effective and relatively safe treatment choice in patients with IIMs, especially for refractory cases. However, further verification via randomized controlled trials is warranted. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - December 12, 2022 Category: Allergy & Immunology Source Type: research
Myositis with prominent b cell aggregates may meet classification criteria for sporadic inclusion body myositis
Through an integrated clinico-sero-pathological approach (1 –3), four autoimmune myositis (AIM) entities are currently defined: immune-mediated necrotizing myopathy (IMNM), antisynthetase syndrome myositis (ASSM), sporadic inclusion body myositis (sIBM) and dermatomyositis (DM). Although T cell aggregates on muscle biopsy have long been described as part o f the pathological hallmark of these myositis entities (4), prominent B cell aggregates are uncommon and less well characterized. (Source: Neuromuscular Disorders)
Source: Neuromuscular Disorders - December 3, 2022 Category: Neurology Authors: Alain Meyer, Yves Troyanov, Pat Korathanakhun, Oc éane Landon-Cardinal, Valérie Leclair, Hughes Allard-Chamard, Josiane Bourré-Tessier, Jean-Paul Makhzoum, Catherine Isabelle, Sandrine Larue, Francois Grand'Maison, Rami Massie, Matthieu Le Page, Anne-M Source Type: research
Clinical characteristics of dysphagic inclusion body myositis
Inclusion body myositis (IBM) is a heterogeneous disease with slowly progressive muscular weakness in the finger flexors, foot extensors, and quadriceps muscles, and life-threatening dysphagia.[1–3] Two-thirds of IBM patients develop dysphagia, and half these patients require tube feeding, resulting in a shorter life exp ectancy.[2] According to some reports, 4.4%–14% of IBM patients present with dysphagia at disease onset,[3,4] while some present solely with dysphagia.[5,6] Overall, little is known about the characteristics of dysphagic IBM patients. (Source: Neuromuscular Disorders)
Source: Neuromuscular Disorders - November 29, 2022 Category: Neurology Authors: Kenichiro Taira, Madoka Mori-Yoshimura, Toshiyuki Yamamoto, Yasushi Oya, Ichizo Nishino, Yuji Takahashi Tags: Research Article Source Type: research
